Drug Safety

, Volume 25, Issue 7, pp 525–535 | Cite as

Management Options for Cancer Therapy-Related Anaemia

Review Article


Anaemia is common in patients with haematological malignancy, occurring in the majority of patients with malignant disease who are treated with chemotherapy. Most patients will have their anaemia attributed to the cytokine-mediated anaemia of chronic disease. Many of these patients with anaemia will be symptomatic with fatigue, which is the single most important symptom reported. Data from many studies indicate that treatment of patients with anaemia with recombinant human erythropoietin (rHuEpo) will increase their haemoglobin level, decrease transfusion need and also improve their quality of life. Recent clinical and experimental work suggest that improving the haemoglobin level may improve the patients’ prognosis but this finding needs to be confirmed.

Treatment of anaemia with rHuEpo in patients with cancer may produce many benefits. Unfortunately, rHuEpo is effective in only around 60% of patients, is slow acting and is expensive. These drawbacks have restricted its use in many healthcare systems. However, a failure to treat anaemia may have important adverse effects for the patient both in terms of their quality of life and, just possibly, in terms of their life expectancy.



Dr Tim J. Littlewood is a paid consultant to one of the companies manufacturing recombinant human erythropoietin. No funding was used in the preparation of this manuscript.


  1. 1.
    San Miguel JF, Garcia-Sanz R, Gonzalez M, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85(2): 448–55Google Scholar
  2. 2.
    Coiffier B. Anemia associated with non-platinum chemotherapy (CT) for Hodgkins lymphoma (HL) or non-Hodgkins lymphoma (NHL) [abstract]. European Cancer Conference (ECCO) 10 Programme 1999; 35: S19Google Scholar
  3. 3.
    Barrett-Lee PJ, Bailey NP, O’Brien MER, et al. Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82: 93–7PubMedCrossRefGoogle Scholar
  4. 4.
    Groopman JE, Itri LM. Chemotherapy induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616–34PubMedCrossRefGoogle Scholar
  5. 5.
    Spivak JL. Recombinant human erythropoietin and the anaemia of cancer. Blood 1994; 84: 997–1004PubMedGoogle Scholar
  6. 6.
    Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322(24): 1689–92PubMedCrossRefGoogle Scholar
  7. 7.
    Cazzola M, Mercuriali F, Brugnara C. Use of recombinant erythropoietin outside the setting of uraemia. Blood 1997; 89: 4248–67PubMedGoogle Scholar
  8. 8.
    Curt GA, Breithart W, Cella D, et al. Impact of cancer related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000; 5: 353–60PubMedCrossRefGoogle Scholar
  9. 9.
    Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Semin Hematol 1997; 34Suppl. 2: 4–12PubMedGoogle Scholar
  10. 10.
    Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528–36PubMedCrossRefGoogle Scholar
  11. 11.
    Glaser C, Millesi W, Kornek GU, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharnyx. Int J Radiat Oncol Biol Phys 2001; 50: 705–15PubMedCrossRefGoogle Scholar
  12. 12.
    Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693–9PubMedCrossRefGoogle Scholar
  13. 13.
    Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of the predictors of response. Blood 1995; 86: 4446–53PubMedGoogle Scholar
  14. 14.
    Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin’s lymphoma-a randomised multicentre study. Blood 1996; 87: 2675–82PubMedGoogle Scholar
  15. 15.
    Dammaco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113: 172–9CrossRefGoogle Scholar
  16. 16.
    Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15(3): 1218–34PubMedGoogle Scholar
  17. 17.
    Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a Prospective Community Oncology study. J Clin Oncol 1998; 16(10): 3412–25PubMedGoogle Scholar
  18. 18.
    Gabrilove JL, Einhorn LH, Livingston RB, et al. Once-weekly dosing of Epoetin alpha is similar to three-times-weekly dosing in increasing haemoglobin and quality of life. J Clin Oncol 2001; 19(11): 2875–82PubMedGoogle Scholar
  19. 19.
    Cleeland CS, Demetri GD, Glaspy J, et al. Identifying haemoglobin level for optimal quality of life: results of an incremental analysis [abstract]. Proc Am Soc Clin Oncol 1999; 18: 2215Google Scholar
  20. 20.
    Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865–74PubMedGoogle Scholar
  21. 21.
    Kelleher DK, Matthiensen U, Thews O, et al. Blood flow, oxygenation and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996; 56: 4728–34PubMedGoogle Scholar
  22. 22.
    Molls M, Stadler P, Becker A, et al. Relevance of oxygen in radiationoncology: mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998; 174Suppl. IV: 13–6PubMedGoogle Scholar
  23. 23.
    Teicher BA, Holden SA, Al-Achi A, et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumour subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res 1990; 50: 3339–44PubMedGoogle Scholar
  24. 24.
    Höckel M, Schlenger K, Hockel S, et al. Association between tumor hypoxia and malignant progression: the clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK, editors. Tumor hypoxia. Stuttgart; Wissenschaftliche Verlagsgesellschaft mbh, 1999: 65–74Google Scholar
  25. 25.
    Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218–34PubMedGoogle Scholar
  26. 26.
    Glaspy J, Colowick A, Heatherington A. Novel erythropoiesis stimulating protein exhibits a prolonged serum half life (t1/2) in oncology patients [abstract]. Proc Am Soc Clin Oncol 2000; 19: 210Google Scholar
  27. 27.
    Ludwig H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anaemia of cancer. Blood 1994; 84: 1056–63PubMedGoogle Scholar
  28. 28.
    Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992; 304: 225–6CrossRefGoogle Scholar
  29. 29.
    Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomised double-blind placebo controlled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998; 103: 1070–4Google Scholar
  30. 30.
    Stein RS, Abels RI, Krantz SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991; 78: 1658–63PubMedGoogle Scholar
  31. 31.
    Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89: 67–71PubMedGoogle Scholar
  32. 32.
    Negrin RS, Stein R, Vardiman J, et al. Treatment of the anaemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor in combination with erythropoietin. Blood 1993; 82: 737–43PubMedGoogle Scholar
  33. 33.
    Hellstrom-Lindberg E, Ahlgren T, Beguin E, et al. Treatment of anaemia in myelodysplastic syndromes with granulocyte colony stimulating factor plus erythropoietin: results from a randomized phase II study and long term follow up of 71 patients. Blood 1998; 92: 68–75PubMedGoogle Scholar
  34. 34.
    Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000; 109: 367–75PubMedCrossRefGoogle Scholar
  35. 35.
    Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposals for a predictive model. Br J Haematol 1997; 99: 344–51PubMedCrossRefGoogle Scholar
  36. 36.
    Hellstrom-Lindberg E, Ahlgren T, Dahl I, et al. A final decision model for treating the anemian of myelodysplastic syndromes (MDS) with Epo and G-CSF [abstract]. Blood 2000; 96: 2347Google Scholar
  37. 37.
    Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and anti erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469–75PubMedCrossRefGoogle Scholar
  38. 38.
    Gershon SK, Luksenburg H, Cote TR, et al. Pure red-cell aplasia and recombinant erythropoietin [letter]. N Engl J Med 2002; 346: 1584–5PubMedCrossRefGoogle Scholar
  39. 39.
    Bunn HF. Sugar in erythropoietin: clinical and forensic implications [comment]. Blood 2002; 99: 1503PubMedCrossRefGoogle Scholar
  40. 40.
    Quirt I, Robeson C, Lau CY, et al. Epoetin alfa increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 2001; 19: 4126–34PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of HaematologyJohn Radcliffe HospitalOxfordUnited Kingdom

Personalised recommendations